Outlook therapeutics® announces commercial launch of lytenava™ (bevacizumab gamma) in germany and the uk for the treatment of wet amd

Lytenava™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet amd in the european union (eu) and united kingdom (uk) 2.8 million injections of repackaged off-label bevacizumab in europe each year 1 iselin, n.j., june 02, 2025 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that lytenava™ (bevacizumab gamma) is now commercially available in germany and the uk for the treatment of wet age-related macular degeneration (wet amd).
AMD Ratings Summary
AMD Quant Ranking